BioLineRx (NASDAQ:BLRX) Upgraded to “Strong-Buy” at Jones Trading

BioLineRx (NASDAQ:BLRX) was upgraded by stock analysts at Jones Trading from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Friday, May 30th, MarketBeat reports.

Several other analysts have also issued reports on the company. Wall Street Zen initiated coverage on BioLineRx in a report on Sunday, May 18th. They set a “sell” rating on the stock. HC Wainwright reaffirmed a “buy” rating on shares of BioLineRx in a report on Wednesday, May 28th.

BioLineRx Stock Up 17.8%

Shares of BioLineRx stock traded up $0.94 during trading on Friday, reaching $6.21. The stock had a trading volume of 465,275 shares, compared to its average volume of 221,587. The stock has a fifty day moving average price of $3.28 and a two-hundred day moving average price of $5.21. BioLineRx has a 52 week low of $2.30 and a 52 week high of $35.60. The company has a market capitalization of $20.66 million, a price-to-earnings ratio of -0.72 and a beta of 1.29. The company has a current ratio of 1.52, a quick ratio of 1.37 and a debt-to-equity ratio of 2.11.

BioLineRx (NASDAQ:BLRX) last released its quarterly earnings data on Tuesday, May 27th. The biotechnology company reported $1.39 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $2.23. The firm had revenue of $11.75 million for the quarter, compared to analyst estimates of $7.72 million. BioLineRx had a negative return on equity of 163.37% and a negative net margin of 90.57%. Sell-side analysts predict that BioLineRx will post -5.8 EPS for the current fiscal year.

Institutional Trading of BioLineRx

A hedge fund recently bought a new stake in BioLineRx stock. Highbridge Capital Management LLC acquired a new position in shares of BioLineRx Ltd. (NASDAQ:BLRX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 1,010,012 shares of the biotechnology company’s stock, valued at approximately $215,000. Highbridge Capital Management LLC owned approximately 50.50% of BioLineRx at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.